Perfluorohexyloctane and lotilaner ophthalmic solution, 2 ocular surface disease drugs, have changed the DED and DB treatment paradigms.

KNOXVILLE, Tenn., Jan. 14, 2025 (GLOBE NEWSWIRE) -- Provectus Biopharmaceuticals, Inc. (“Provectus” or the “Company”) (OTCQB: PVCT) today announced a $3 million seed financing round for VisiRose, Inc.

Aging Population and Pipeline Launches Fuel Rapid Growth in Ophthalmic Pharma MarketDublin, Jan. 13, 2025 (GLOBE NEWSWIRE) -- The "Ophthalmic Drugs Market Report 2025-2035" has been added to ...

Lupin receives US FDA tentative approval for loteprednol etabonate ophthalmic gel: Our Bureau, Mumbai Thursday, January 9, 2025, 17:20 Hrs [IST] Global pharma major Lupin Limited ...

Catch up on the clinical trial news, updates from the United States Food and Drug Administration (FDA), and company funding ...

You might just know someone, close or distant, who has struggled with drug addiction at one point in time. It could be a distant relative or someone you went to school with, but the sheer probability ...

Substance abuse in the United States is one of the leading health conditions impacting millions of lives and due to many types of drug addictions. Since 2000, there have been 700,000 overdose deaths ...

This site displays a prototype of a “Web 2.0” version of the daily Federal Register. It is not an official legal edition of the Federal Register, and does not replace the official print version or the ...

The ophthalmic nerve is the first branch of the trigeminal nerve, which is also known as the fifth cranial nerve. The ophthalmic nerve supplies sensory innervation to the structures of the eye, ...

A recent survey reveals a significant decline in teen drug and alcohol use since 2017, reaching its lowest point in 2024. Researchers attribute this drop to pandemic lockdowns disrupting social ...

ABSTRACT: The assessment of extractable and leachables (E&L) has become a cornerstone of pharmaceutical product safety, yet no unified global standards currently exist to quantify or report E&L from ...